MX2018015709A - Derivados de azabencimidazol como inhibidores de pi3k beta. - Google Patents

Derivados de azabencimidazol como inhibidores de pi3k beta.

Info

Publication number
MX2018015709A
MX2018015709A MX2018015709A MX2018015709A MX2018015709A MX 2018015709 A MX2018015709 A MX 2018015709A MX 2018015709 A MX2018015709 A MX 2018015709A MX 2018015709 A MX2018015709 A MX 2018015709A MX 2018015709 A MX2018015709 A MX 2018015709A
Authority
MX
Mexico
Prior art keywords
beta inhibitors
pi3k beta
azabenzimidazole derivatives
compounds
azabenzimidazole
Prior art date
Application number
MX2018015709A
Other languages
English (en)
Inventor
René Angibaud Patrick
Sophie Poncelet Virginie
Meerpoel Lieven
Noëlle Constance Pilatte Isabelle
Alexis Georges Querolle Olivier
Anne Mevellec Laurence
Thérèse Jeanne Pasquier Elisabeth
Jean Maurice MERCEY Guillaume
Meyer Christophe
Gabriel Marcel DEMESTRE Christophe
Jean- Claude Berthelot Didier
Coupa Sophie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018015709A publication Critical patent/MX2018015709A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a derivados de azabencimidazol de Formula (I) (ver fórmula) en donde las variables tienen el significado definido en las reivindicaciones; Los compuestos de acuerdo con la presente invencion son utiles como inhibidores pI3Kß; la invencion se refiere ademas a composiciones farmaceuticas que comprenden dichos compuestos como principio activo, asi como tambien al uso de dichos compuestos como un medicamento.
MX2018015709A 2016-06-16 2017-06-15 Derivados de azabencimidazol como inhibidores de pi3k beta. MX2018015709A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16174712 2016-06-16
PCT/EP2017/064672 WO2017216293A1 (en) 2016-06-16 2017-06-15 Azabenzimidazole derivatives as pi3k beta inhibitors

Publications (1)

Publication Number Publication Date
MX2018015709A true MX2018015709A (es) 2019-03-21

Family

ID=56132833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015709A MX2018015709A (es) 2016-06-16 2017-06-15 Derivados de azabencimidazol como inhibidores de pi3k beta.

Country Status (13)

Country Link
US (1) US20190263804A1 (es)
EP (1) EP3472147B1 (es)
JP (1) JP7158286B2 (es)
KR (1) KR102472198B1 (es)
CN (1) CN109311843B (es)
AU (1) AU2017286380B2 (es)
BR (1) BR112018076169A2 (es)
CA (1) CA3025746A1 (es)
EA (1) EA037871B1 (es)
ES (1) ES2818620T3 (es)
IL (1) IL263653A (es)
MX (1) MX2018015709A (es)
WO (1) WO2017216293A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010671A (es) 2018-04-12 2020-10-28 Bayer Ag Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-11-[1-(pirim idin-2-il)-1h-1,2,4-triazol-5-il] etilibenzamida y los derivados de piridinacarboxamida correspondientes como plaguicidas.
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
SG11202010068VA (en) 2018-04-25 2020-11-27 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
AU2020318590A1 (en) 2019-07-23 2022-02-17 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
CN110551101B (zh) * 2019-08-28 2020-11-24 沈阳药科大学 1、6-二取代-苯并五元杂环类衍生物及其用途
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
KR20220132593A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2021154667A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230118688A1 (en) 2020-01-27 2023-04-20 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230130516A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115279765A (zh) 2020-01-27 2022-11-01 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
US20230041738A1 (en) 2020-01-27 2023-02-09 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230131192A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097104A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2023155866A1 (zh) * 2022-02-18 2023-08-24 四川海思科制药有限公司 一种吡唑并吡啶衍生物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
EP1993537A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc THIAZOLONES AS INHIBITORS OF P13-KINASES
US20090215818A1 (en) 2006-07-24 2009-08-27 Smithkline Beecham Corporation Thiozolidinedione derivatives as pi3 kinase inhibitors
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
KR101701109B1 (ko) * 2007-10-05 2017-02-13 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
CA2775942A1 (en) 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
WO2012047538A1 (en) 2010-10-06 2012-04-12 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
WO2013095761A1 (en) 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
BR112018076169A2 (pt) 2019-03-26
JP2019518059A (ja) 2019-06-27
AU2017286380A1 (en) 2018-12-06
AU2017286380B2 (en) 2021-02-04
EA037871B1 (ru) 2021-05-28
KR102472198B1 (ko) 2022-11-28
EA201892734A1 (ru) 2019-05-31
ES2818620T3 (es) 2021-04-13
EP3472147A1 (en) 2019-04-24
IL263653A (en) 2019-01-31
CA3025746A1 (en) 2017-12-21
WO2017216293A1 (en) 2017-12-21
KR20190016976A (ko) 2019-02-19
JP7158286B2 (ja) 2022-10-21
CN109311843A (zh) 2019-02-05
CN109311843B (zh) 2021-10-08
EP3472147B1 (en) 2020-06-17
US20190263804A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12018500425A1 (en) Novel 6-6 bicyclic aromatic ring substituted nuceloside analogues for use as prmt5 inhibitors
MX2015017192A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2020005944A (es) Analogos espirobiciclicos novedosos.
MX367914B (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
WO2015191754A3 (en) Phosphatidylinositol 3-kinase inhibitors
NZ725399A (en) Macrocylic pyrimidine derivatives
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2018015707A (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.
WO2014106826A3 (en) Anthracycline analogue and uses thereof
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12018501895A1 (en) Substituted nucleoside analogues for use as prmt5 inhibitors
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.
MX2019011610A (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.

Legal Events

Date Code Title Description
FG Grant or registration